Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Mutant-Selective T-cell Receptor Therapy for Solid Tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
Emerging strategies for treating metastasis
10.1038/s43018-021-00181-0 · 2021 · External reference
Targeting metastatic cancer
10.1038/s41591-020-01195-4 · 2021 · External reference
Tumor microenvironment complexity: emerging roles in cancer therapy
10.1158/0008-5472.can-12-0122 · 2012 · External reference
Intratumor heterogeneity: the rosetta stone of therapy resistance
10.1016/j.ccell.2020.03.007 · 2020 · External reference
Immune escape: a critical hallmark in solid tumors
10.1016/j.lfs.2020.118110 · 2020 · External reference
New and emerging targeted treatments in advanced non-small-cell lung cancer
10.1016/s0140-6736(16)31473-8 · 2016 · External reference
Melanoma
10.1016/s0140-6736(18)31559-9 · 2018 · External reference
Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy
10.3389/fimmu.2024.1336023 · 2024 · External reference
Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
10.1158/2326-6066.cir-15-0097 · 2015 · External reference
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
10.1038/s41467-023-40850-5 · 2023 · External reference
Extracellular matrix cancer-associated fibroblasts promote stromal fibrosis and immune exclusion in triple-negative breast cancer
10.1002/path.6395 · 2025 · External reference
Pancreatic cancer: a review
10.1001/jama.2021.13027 · 2021 · External reference
MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway
10.1038/s41388-019-1045-6 · 2020 · External reference
Cancer genome landscapes
10.1126/science.1235122 · 2013 · External reference
Mutational landscape of cancer-driver genes across human cancers
10.1038/s41598-023-39608-2 · 2023 · External reference
Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives
10.3390/ijms25105489 · 2024 · External reference
Targeted therapy for non-small cell lung cancer: first line and beyond
10.1016/j.hoc.2023.02.009 · 2023 · External reference
Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
10.1016/j.critrevonc.2020.103119 · 2020 · External reference
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
10.1186/s12943-023-01805-y · 2023 · External reference
Unveiling the mechanisms and challenges of cancer drug resistance
10.1186/s12964-023-01302-1 · 2024 · External reference
A pneumatic laparoscope holder controlled by head movement
10.1002/rcs.1606 · 2015 · External reference
A decade of immune-checkpoint inhibitors in cancer therapy
10.1038/s41467-020-17670-y · 2020 · External reference
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
10.1038/s41573-018-0007-y · 2019 · External reference
Engineered T cells for cancer therapy
10.1007/s00262-014-1568-1 · 2014 · External reference
TCR-engineered T cell therapy in solid tumors: state of the art and perspectives
10.1126/sciadv.adf3700 · 2023 · External reference
Degradation of cell proteins and the generation of MHC class I-presented peptides
10.1146/annurev.immunol.17.1.739 · 1999 · External reference
MHC I assembly and peptide editing - chaperones, clients, and molecular plasticity in immunity
10.1016/j.coi.2021.02.004 · 2021 · External reference
The HLA system. First of two parts
10.1056/nejm200009073431006 · 2000 · External reference
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
10.4049/jimmunol.153.12.5586 · 1994 · External reference
The cell biology of MHC class I antigen presentation
10.1034/j.1399-0039.2002.590103.x · 2002 · External reference
The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells
10.1002/eji.1830271230 · 1997 · External reference
T cell killing does not require the formation of a stable mature immunological synapse
10.1038/ni1058 · 2004 · External reference
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
10.1038/s41416-020-01048-4 · 2021 · External reference
Hitting the target: how T cells detect and eliminate tumors
10.4049/jimmunol.1701413 · 2018 · External reference
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
10.1126/science.7513441 · 1994 · External reference
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
10.4049/jimmunol.154.8.3961 · 1995 · External reference
Immunotherapy in non-small cell lung cancer: past, present, and future directions
10.3389/fonc.2022.877594 · 2022 · External reference
The immunobiology of cancer immunosurveillance and immunoediting
10.1016/j.immuni.2004.07.017 · 2004 · External reference
The three Es of cancer immunoediting
10.1146/annurev.immunol.22.012703.104803 · 2004 · External reference
New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape
10.1016/j.coi.2014.01.004 · 2014 · External reference
Hallmarks of cancer: the next generation
10.1016/j.cell.2011.02.013 · 2011 · External reference
T cell dysfunction in cancer
10.1016/j.ccell.2018.03.012 · 2018 · External reference
T cell dysfunction in cancer immunity and immunotherapy
10.3389/fimmu.2019.01719 · 2019 · External reference
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
10.1038/nature03954 · 2005 · External reference
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression
10.1016/j.ccr.2010.11.011 · 2011 · External reference
Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity
10.1098/rspb.1954.0054 · 1954 · External reference
Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
10.1016/j.ejca.2022.05.008 · 2022 · External reference
Selective in vitro growth of T lymphocytes from normal human bone marrows
10.1126/science.181845 · 1976 · External reference
Structure and expression of a cloned cDNA for human interleukin-2
10.1038/302305a0 · 1983 · External reference
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
10.1056/nejm198512053132327 · 1985 · External reference
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
10.1097/00002371-200205000-00007 · 2002 · External reference
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
10.1158/1078-0432.ccr-11-0116 · 2011 · External reference
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
10.1093/jnci/86.15.1159 · 1994 · External reference
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
10.1073/pnas.90.2.720 · 1993 · External reference
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
10.1073/pnas.86.24.10024 · 1989 · External reference
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
10.1158/1078-0432.ccr-06-1183 · 2006 · External reference
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience
10.1200/jco.2006.05.9964 · 2006 · External reference
Graft-versus-leukemia reactions after bone marrow transplantation
10.1182/blood.v75.3.555.555 · 1990 · External reference
T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection
10.1158/2326-6066.cir-18-0277 · 2018 · External reference
TCR redirected T cells for cancer treatment: achievements, hurdles, and goals
10.3389/fimmu.2020.01689 · 2020 · External reference
Neoantigen T-cell receptor gene therapy in pancreatic cancer
10.1056/nejmoa2119662 · 2022 · External reference
Engineered T cell therapy for viral and non-viral epithelial cancers
10.1016/j.ccell.2022.10.016 · 2023 · External reference
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy
10.1016/j.cell.2023.06.020 · 2023 · External reference
Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study
10.1200/jco-25-00765 · 2025 · External reference
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
10.1016/s0140-6736(24)00319-2 · 2024 · External reference
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions
10.1080/14712598.2022.2064711 · 2022 · External reference
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
10.1038/s41591-018-0266-5 · 2019 · External reference
Clonality, antigen recognition, and suppression of CD8+ T cells differentially affect prognosis of breast cancer subtypes
10.1158/1078-0432.ccr-19-0285 · 2020 · External reference
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
10.1136/jitc-2020-000668 · 2020 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
Resistance to immunotherapy in human malignancies: mechanisms, research progresses, challenges, and opportunities
10.1002/jcp.30575 · 2022 · External reference
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
10.1136/jitc-2022-005755 · 2022 · External reference
Endogenous T-cell therapy: clinical experience
10.1097/ppo.0000000000000158 · 2015 · External reference
Tumor-specific CD8+ T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes
10.1136/jitc-2024-009367 · 2025 · External reference
The basic principles of chimeric antigen receptor design
10.1158/2159-8290.cd-12-0548 · 2013 · External reference
The promise and potential pitfalls of chimeric antigen receptors
10.1016/j.coi.2009.02.009 · 2009 · External reference
Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy
10.1200/jco.20.01467 · 2020 · External reference
Long-term outcomes following CAR T cell therapy: what we know so far
10.1038/s41571-023-00754-1 · 2023 · External reference
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
10.1056/nejmoa1910607 · 2020 · External reference
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
10.1038/s41591-023-02785-8 · 2024 · External reference
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
10.1056/nejmoa1804980 · 2019 · External reference
KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
10.1056/nejmoa1914347 · 2020 · External reference
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
10.1038/s41591-021-01622-0 · 2022 · External reference
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
10.1016/s1470-2045(21)00591-x · 2022 · External reference
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
10.1056/nejmoa1709866 · 2018 · External reference
FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
10.1158/1078-0432.ccr-18-2743 · 2019 · External reference
Survival with axicabtagene ciloleucel in large B-cell lymphoma
10.1056/nejmoa2301665 · 2023 · External reference
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
10.1016/s0140-6736(21)00933-8 · 2021 · External reference
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
10.1056/nejmoa2024850 · 2021 · External reference
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma
10.1182/hematology.2025000721 · 2025 · External reference
Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis
10.1016/j.eclinm.2025.103267 · 2025 · External reference
Current understanding and management of CAR T cell-associated toxicities
10.1038/s41571-024-00903-0 · 2024 · External reference
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
10.1016/j.ymthe.2023.06.006 · 2023 · External reference
Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers
10.1016/j.ymthe.2017.03.010 · 2017 · External reference
634 EVEREST-1: a seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
2023 · External reference
Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion
10.1200/jco.2024.42.16_suppl.3514 · 2024 · External reference
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
10.1038/s41591-023-02452-y · 2023 · External reference
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
10.1136/jitc-2021-003826 · 2022 · External reference
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
10.1186/s13045-019-0704-y · 2019 · External reference
The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
10.1016/j.omto.2021.02.013 · 2021 · External reference
Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
10.1002/cti2.1283 · 2021 · External reference
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
10.1038/s41591-024-02875-1 · 2024 · External reference
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma
10.1093/neuonc/noac024 · 2022 · External reference
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
10.1038/s43018-024-00749-6 · 2024 · External reference
HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
10.1038/s41419-021-04100-0 · 2021 · External reference
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
10.1136/jitc-2023-008566 · 2024 · External reference
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors
10.1038/s41467-024-53265-7 · 2024 · External reference
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
10.1038/s41591-024-02979-8 · 2024 · External reference
Mucin-1-targeted chimeric antigen receptor T cells are effective and safe in controlling solid tumors in immunocompetent host
10.1097/cji.0000000000000505 · 2024 · External reference
Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
10.1038/s41598-021-85747-9 · 2021 · External reference
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
10.1038/s41591-024-03037-z · 2024 · External reference
Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers
10.1158/1078-0432.ccr-24-1853 · 2024 · External reference
CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: results of ELIMYN18.2 phase 1b clinical trial
10.1200/jco.2024.42.3_suppl.356 · 2024 · External reference
Outstanding safety and efficacy data of IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced solid tumors
10.1200/jco.2024.42.16_suppl.e16012 · 2024 · External reference
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
10.1126/sciadv.adg9721 · 2023 · External reference
Efficacy of EpCAM CAR-T IMC001 in advanced gastric cancers
10.1200/jco.2024.42.16_suppl.4043 · 2024 · External reference
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
10.1038/s41586-024-08261-8 · 2025 · External reference
Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)
10.1200/jco.2024.42.16_suppl.4019 · 2024 · External reference
GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma
10.1038/s41401-024-01287-8 · 2024 · External reference
Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors
10.1200/jco.2024.42.16_suppl.2543 · 2024 · External reference
B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer
10.1038/s41420-023-01453-7 · 2023 · External reference
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
10.1038/s41591-024-03451-3 · 2025 · External reference
Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models
10.1158/1078-0432.ccr-23-3298 · 2024 · External reference
Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM
10.1200/jco.2024.42.16_suppl.2062 · 2024 · External reference
STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed/refractory solid tumors
10.1200/jco.23.02229 · 2024 · External reference
The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research
10.1158/1078-0432.ccr-09-0737 · 2009 · External reference
Tumor-specific shared antigenic peptides recognized by human T cells
10.1034/j.1600-065x.2002.18806.x · 2002 · External reference
Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer
10.3390/cells10092379 · 2021 · External reference
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
10.1038/nm.3161 · 2013 · External reference
Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
10.1016/j.ccell.2020.07.013 · 2020 · External reference
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
10.1016/j.iotech.2022.100089 · 2022 · External reference
Tumour-associated antigens and their anti-cancer applications
2017 · External reference
Cancer regression in patients after transfer of genetically engineered lymphocytes
10.1126/science.1129003 · 2006 · External reference
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
10.1182/blood-2009-03-211714 · 2009 · External reference
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma
10.1158/1078-0432.ccr-13-3017 · 2014 · External reference
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
10.1038/mt.2010.272 · 2011 · External reference
Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma
10.1158/2159-8290.cd-17-1417 · 2018 · External reference
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
10.1186/s40425-019-0762-2 · 2019 · External reference
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
10.1002/ijc.1451 · 2001 · External reference
Tumor antigen expression in melanoma varies according to antigen and stage
10.1158/1078-0432.ccr-05-1544 · 2006 · External reference
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
10.1073/pnas.94.5.1914 · 1997 · External reference
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
10.1097/cji.0b013e3182829903 · 2013 · External reference
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer
10.1136/jitc-2021-003581 · 2022 · External reference
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
10.1182/blood-2013-03-490565 · 2013 · External reference
Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3
10.1200/jco.2017.74.5463 · 2017 · External reference
Generation of Epstein-Barr virus antigen-specific T cell receptors recognizing immunodominant epitopes of LMP1, LMP2A, and EBNA3C for immunotherapy
10.1089/hum.2020.283 · 2021 · External reference
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
10.1038/s41591-020-01225-1 · 2021 · External reference
Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6
10.1158/1078-0432.ccr-14-3341 · 2015 · External reference
T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study
10.1200/jco.18.02424 · 2019 · External reference
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial
10.1007/s12072-021-10250-2 · 2021 · External reference
Immunosuppressive drug-resistant armored T-cell receptor T cells for immune therapy of HCC in liver transplant patients
10.1002/hep.31662 · 2021 · External reference
Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
10.3389/fimmu.2022.1079515 · 2022 · External reference
Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood
10.1053/j.gastro.2018.07.058 · 2019 · External reference
Analysis of intraepithelial lymphocytes and Peyer’s patch lymphoid tissue in TCR-alpha knockout mice
10.1007/978-1-4615-1941-6_21 · 1995 · External reference
Mutational heterogeneity in cancer and the search for new cancer-associated genes
10.1038/nature12213 · 2013 · External reference
Targeting public neoantigens for cancer immunotherapy
10.1038/s43018-021-00210-y · 2021 · External reference
Discovery and characterization of actionable tumor antigens
10.1186/s13073-019-0642-x · 2019 · External reference
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
10.1186/s13073-019-0636-8 · 2019 · External reference
The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy
10.1007/s00262-003-0480-x · 2004 · External reference
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
10.1016/j.crmeth.2021.100084 · 2021 · External reference
Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy
10.1016/j.biopha.2019.109542 · 2019 · External reference
LinkedOmics: analyzing multi-omics data within and across 32 cancer types
10.1093/nar/gkx1090 · 2018 · External reference
PepQuery2 democratizes public MS proteomics data for rapid peptide searching
10.1038/s41467-023-37462-4 · 2023 · External reference
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence
10.1371/journal.pone.0000796 · 2007 · External reference
Systematically benchmarking peptide-MHC binding predictors: from synthetic to naturally processed epitopes
10.1371/journal.pcbi.1006457 · 2018 · External reference
Numbers and odds: TCR repertoire size and its age changes impacting on T cell functions
10.1016/j.smim.2023.101810 · 2023 · External reference
On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands
10.1146/annurev-immunol-030409-101253 · 2010 · External reference
Exploring the pre-immune landscape of antigen-specific T cells
10.1186/s13073-018-0577-7 · 2018 · External reference
The human T-cell receptor. Structure and function
10.1056/nejm198504253121706 · 1985 · External reference
A single autoimmune T cell receptor recognizes more than a million different peptides
10.1074/jbc.m111.289488 · 2012 · External reference
T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes
10.1038/nbt.4303 · 2018 · External reference
An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors
10.1016/j.ymthe.2017.10.018 · 2018 · External reference
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
10.1136/jitc-2021-002595 · 2021 · External reference
A humanized TCR retaining authentic specificity and affinity conferred potent anti-tumour cytotoxicity
10.1111/imm.12935 · 2018 · External reference
Transgenic mice with a diverse human T cell antigen receptor repertoire
10.1038/nm.2197 · 2010 · External reference
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice
10.1038/nbt.3147 · 2015 · External reference
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies
10.1002/eji.201242606 · 2012 · External reference
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
10.1073/pnas.1221609110 · 2013 · External reference
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
10.4049/jimmunol.180.9.6116 · 2008 · External reference
Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects
10.3389/fimmu.2022.835762 · 2022 · External reference
TCRs with high affinity for foreign pMHC show self-reactivity
10.1038/ni863 · 2003 · External reference
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines
10.4049/jimmunol.179.9.5845 · 2007 · External reference
The Goldilocks model for TCR-too much attraction might not be best for vaccine design
10.1371/journal.pbio.1000482 · 2010 · External reference
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
10.1038/ni1443 · 2007 · External reference
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
10.1038/ni.1679 · 2009 · External reference
Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy
10.1084/jem.183.4.1917 · 1996 · External reference
Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen
2001 · External reference
Engineering strategies to enhance TCR-based adoptive T cell therapy
10.3390/cells9061485 · 2020 · External reference
Cooperative armoring of CAR and TCR T cells by T cell-restricted IL15 and IL21 universally enhances solid tumor efficacy
10.1158/1078-0432.ccr-23-1872 · 2024 · External reference
A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma
10.1038/s41392-024-01792-6 · 2024 · External reference
T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity
10.3390/cancers14081998 · 2022 · External reference
Double strike approach for tumor attack: engineering T cells using a CD40L:CD28 chimeric co-stimulatory switch protein for enhanced tumor targeting in adoptive cell therapy
10.3389/fimmu.2021.750478 · 2021 · External reference
CD3 limits the efficacy of TCR gene therapy in vivo
10.1182/blood-2011-04-346338 · 2011 · External reference
TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity
10.4049/jimmunol.1302074 · 2014 · External reference
Introduction of genetically modified CD3ζ improves proliferation and persistence of antigen-specific CTLs
10.1158/2326-6066.cir-17-0538 · 2018 · External reference
Design of high-specificity binders for peptide-MHC-I complexes
10.1126/science.adv0185 · 2025 · External reference
De novo design of protein structure and function with RFdiffusion
10.1038/s41586-023-06415-8 · 2023 · External reference
Genome-editing technologies in adoptive T cell immunotherapy for cancer
10.1007/s11899-017-0417-7 · 2017 · External reference
The next generation of CRISPR-Cas technologies and applications
10.1038/s41580-019-0131-5 · 2019 · External reference
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
10.1182/blood-2017-05-787598 · 2018 · External reference
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function
10.1126/scitranslmed.abg8027 · 2022 · External reference
Non-viral precision T cell receptor replacement for personalized cell therapy
10.1038/s41586-022-05531-1 · 2023 · External reference
Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering
10.1016/j.omtm.2023.101139 · 2023 · External reference
Customizable mRNA lipid nanoparticles for transfection of primary human T cells
10.1021/acsnano.5c15903 · 2025 · External reference
A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes
10.1007/s00262-005-0098-2 · 2006 · External reference
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study
10.1200/jco.2023.41.16_suppl.2547 · 2023 · External reference
Process development for adoptive cell therapy in academia: a pipeline for clinical-scale manufacturing of multiple TCR-T cell products
10.3389/fimmu.2022.896242 · 2022 · External reference
Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy
10.3390/ijms20246223 · 2019 · External reference
CD4+CD25− T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model
10.4049/jimmunol.181.2.1063 · 2008 · External reference
Most do, but some do not: CD4+CD25− T cells, but not CD4+CD25+ Treg cells, are cytolytic when redirected by a chimeric antigen receptor (CAR)
10.3390/cancers9090112 · 2017 · External reference
Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms
10.1038/s41417-020-0183-x · 2021 · External reference
Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties
10.1074/jbc.m700976200 · 2007 · External reference
Single-cell transcriptomics reveals killing mechanisms of antitumor cytotoxic CD4+ TCR-T cells
10.3389/fimmu.2022.939940 · 2022 · External reference
Role of memory T cell subsets for adoptive immunotherapy
10.1016/j.smim.2016.02.001 · 2016 · External reference
A human memory T cell subset with stem cell-like properties
10.1038/nm.2446 · 2011 · External reference
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
10.1038/s41408-024-01193-6 · 2024 · External reference
Insights into the relationship between toll like receptors and gamma delta T cell responses
10.3389/fimmu.2014.00366 · 2014 · External reference
CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
2025 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
10.1136/jitc-2021-003715 · 2022 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
MHC class II restricted neoantigen: a promising target in tumor immunotherapy
10.1016/j.canlet.2016.12.039 · 2017 · External reference
Unlock the code of MHC II-enabled cancer immunotherapy
10.1016/j.critrevonc.2025.104813 · 2025 · External reference
HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
10.1038/s41467-024-46558-4 · 2024 · External reference
Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy
10.1016/j.ymthe.2020.11.019 · 2021 · External reference
Identification and validation of T-cell receptors targeting RAS hotspot mutations in human cancers for use in cell-based immunotherapy
10.1158/1078-0432.ccr-21-0849 · 2021 · External reference
CIITA-driven MHC class II expressing tumor cells as antigen presenting cell performers: toward the construction of an optimal anti-tumor vaccine
10.3389/fimmu.2019.01806 · 2019 · External reference
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses
10.1016/j.ccell.2022.09.007 · 2022 · External reference
Small-molecule MHC-II inducers promote immune detection and anti-cancer immunity via editing cancer metabolism
10.1016/j.chembiol.2023.05.003 · 2023 · External reference
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
10.1186/s40364-023-00534-0 · 2023 · External reference
Personalized vaccines for cancer immunotherapy
10.1126/science.aar7112 · 2018 · External reference
Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors
10.1158/2326-6066.cir-22-0040 · 2022 · External reference
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
10.1016/j.ymthe.2024.04.009 · 2024 · External reference
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
10.1038/s41591-024-03109-0 · 2024 · External reference
RAS isoforms and mutations in cancer at a glance
10.1242/jcs.182873 · 2016 · External reference
Characterization of KRAS mutation subtypes in non-small cell lung cancer
10.1158/1535-7163.mct-21-0201 · 2021 · External reference
Targeting KRAS G12C mutation in colorectal cancer, a review: new arrows in the quiver
10.3390/ijms25063304 · 2024 · External reference
Targeting KRAS in cancer
10.1038/s41591-024-02903-0 · 2024 · External reference
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
10.1038/s41575-019-0245-4 · 2020 · External reference
Immune modulatory effects of oncogenic KRAS in cancer
10.1038/s41467-020-19288-6 · 2020 · External reference
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
10.1172/jci155523 · 2022 · External reference
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
10.1038/s41467-021-26214-x · 2021 · External reference
Chimeric antigen receptors directed at mutant KRAS exhibit an inverse relationship between functional potency and neoantigen selectivity
10.1158/2767-9764.crc-21-0165 · 2022 · External reference
AFNT-211: an FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors
10.1200/jco.2023.41.16_suppl.2543 · 2023 · External reference
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
10.1038/s41467-023-42010-1 · 2023 · External reference
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
10.3389/fimmu.2023.1161538 · 2023 · External reference
EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer
10.1158/2159-8290.cd-20-0187 · 2020 · External reference
RAS mutation-specific responses to paralog- and state-selective RAS inhibitors
10.1158/1541-7786.mcr-25-0319 · 2026 · External reference
Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
10.1002/1878-0261.13751 · 2025 · External reference
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
10.1158/0008-5472.can-11-3747 · 2012 · External reference
Discovery of RGT-018: a potent, selective, and orally bioavailable SOS1 inhibitor for KRAS-driven cancers
10.1158/1535-7163.mct-24-0049 · 2024 · External reference
KRAS mutations in non-small cell lung cancer: translational aspects, current therapies and challenges for future research
10.1016/j.critrevonc.2025.104925 · 2025 · External reference
Breaking the “undruggable” barrier: anti-PD-1/PD-L1 immunotherapy for non-small cell lung cancer patients with KRAS mutations-a comprehensive review and description of single site experience
10.3390/cancers15143732 · 2023 · External reference
Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis
10.1007/s40291-021-00563-1 · 2022 · External reference
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
10.1016/s1470-2045(16)30624-6 · 2017 · External reference
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
10.1016/s0140-6736(16)32517-x · 2017 · External reference
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
10.1056/nejmoa1507643 · 2015 · External reference
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
10.1016/s1470-2045(18)30144-x · 2018 · External reference
A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC
10.1016/j.jtho.2018.03.035 · 2018 · External reference
A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for patients with EGFR mutation-positive nonsquamous non-small-cell lung cancer who acquire resistance to tyrosine kinase inhibitors not due to a secondary T790M mutation: rationale and protocol design for the WJOG8515L study
10.1016/j.cllc.2017.05.012 · 2017 · External reference
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
10.1093/annonc/mdx076 · 2017 · External reference
Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial
10.1172/jci.insight.152631 · 2022 · External reference
Endogenous CD4+ T cells recognize neoantigens in lung cancer patients, including recurrent oncogenic KRAS and ERBB2 (Her2) driver mutations
10.1158/2326-6066.cir-18-0402 · 2019 · External reference
Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice
10.1038/s41419-017-0238-6 · 2018 · External reference
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
10.1136/jitc-2021-002531 · 2021 · External reference
Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review
10.1001/jamaneurol.2024.3818 · 2025 · External reference
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker
10.1038/s41467-024-54129-w · 2024 · External reference
Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors
10.1001/jamaoncol.2016.0891 · 2016 · External reference
PIK3CA in colorectal cancer
10.3389/fonc.2014.00035 · 2014 · External reference
Analysis of PIK3CA mutation prevalence variation among colorectal cancer populations: a comprehensive review
2025 · External reference
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
10.1038/s41591-022-01786-3 · 2022 · External reference
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations
10.1007/s00262-024-03729-y · 2024 · External reference
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
10.1002/humu.20495 · 2007 · External reference
Arming “old guards” with “new dual-targeting weapons”
10.1016/j.ccell.2021.04.010 · 2021 · External reference
Targeting a neoantigen derived from a common TP53 mutation
10.1126/science.abc8697 · 2021 · External reference
Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-A*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation
10.1200/jco.2024.42.16_suppl.e14514 · 2024 · External reference
Non-clinical evaluation of NT-175, an autologous T cell product engineered to express an HLA-A*02:01-restricted TCR targeting TP53 R175H and resistant to TGF-b inhibition
10.1200/jco.2024.42.16_suppl.2560 · 2024 · External reference
CLSP-1025, a novel bispecific T-cell engager targeting a p53 R175H mutant peptide presented by HLA-A*02:01
2024 · External reference
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
10.1073/pnas.0710929105 · 2008 · External reference
Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy
10.1007/s00262-019-02401-0 · 2019 · External reference
Dual TCR T cells: identity crisis or multitaskers?
10.4049/jimmunol.1800904 · 2019 · External reference
TCRα reporter mice reveal contribution of dual TCRα expression to T cell repertoire and function
10.1073/pnas.2013188117 · 2020 · External reference
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
10.1038/nm.2128 · 2010 · External reference
Mixed T cell receptor dimers harbor potentially harmful neoreactivity
10.1073/pnas.1005802107 · 2010 · External reference
Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains
10.1038/gt.2011.104 · 2012 · External reference
Domain-swapped T cell receptors improve the safety of TCR gene therapy
10.7554/elife.19095 · 2016 · External reference
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function
10.1038/s41551-019-0409-0 · 2019 · External reference
The structure of the T cell antigen receptor
10.1146/annurev.immunol.14.1.563 · 1996 · External reference
T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4
10.1074/jbc.ra120.014016 · 2020 · External reference
Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors
10.1126/sciadv.adg9845 · 2023 · External reference
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells
10.1158/1078-0432.ccr-13-0458 · 2013 · External reference
Blockade of CTLA-4 and PD-1 enhances adoptive T-cell therapy efficacy in an ICOS-mediated manner
10.1158/2326-6066.cir-18-0873 · 2019 · External reference
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
10.1038/s41573-023-00809-z · 2023 · External reference
Overall survival benefit with tebentafusp in metastatic uveal melanoma
10.1056/nejmoa2103485 · 2021 · External reference
Bispecific antibodies versus chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a comparative narrative review of efficacy, safety, and accessibility
10.1002/cam4.71562 · 2026 · External reference
CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis
10.1182/blood.2023023419 · 2024 · External reference
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
10.1136/jitc-2024-010064 · 2024 · External reference
The IPD and IMGT/HLA database: allele variant databases
10.1093/nar/gku1161 · 2015 · External reference
Engineered T-cell receptor T cells for cancer immunotherapy
10.1158/2326-6066.cir-21-0269 · 2021 · External reference
Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing
10.1038/cmi.2013.33 · 2013 · External reference
Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity
10.1001/jamanetworkopen.2023.38612 · 2023 · External reference
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations
10.1016/j.trecan.2025.08.013 · 2025 · External reference
MHC-I genotype restricts the oncogenic mutational landscape
10.1016/j.cell.2017.09.050 · 2017 · External reference
Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry
10.1186/s13045-022-01373-6 · 2022 · External reference
Sensitive detection and analysis of neoantigen-specific T cell populations from tumors and blood
10.1016/j.celrep.2019.07.106 · 2019 · External reference
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
10.1038/nrc2355 · 2008 · External reference
Allele-specific HLA loss and immune escape in lung cancer evolution
10.1016/j.cell.2017.10.001 · 2017 · External reference
Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome
1999 · External reference
Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response
10.1158/2159-8290.cd-20-0672 · 2021 · External reference
A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity
10.1038/s41467-022-29203-w · 2022 · External reference
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
10.1038/s41698-024-00665-z · 2024 · External reference
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
10.1136/jitc-2023-006930 · 2023 · External reference
Immunotherapy resistance by inflammation-induced dedifferentiation
10.1158/2159-8290.cd-17-1178 · 2018 · External reference
Isolation and characterization of an HLA-DRB1*04-restricted HPV16-E7 T cell receptor for cancer immunotherapy
10.1089/hum.2018.091 · 2018 · External reference
Mechanisms controlling PD-L1 expression in cancer
10.1016/j.molcel.2019.09.030 · 2019 · External reference
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages
10.1158/1078-0432.ccr-12-3314 · 2013 · External reference
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
10.1084/jem.20082173 · 2009 · External reference
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
10.18632/oncotarget.24283 · 2018 · External reference
The wild west of checkpoint inhibitor development
10.1056/nejmp2116863 · 2022 · External reference
A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab
10.1158/1078-0432.ccr-18-3496 · 2019 · External reference
Infusion product TNFα, Th2, and STAT3 activities are associated with clinical responses to transgenic T-cell receptor cell therapy
10.1158/2326-6066.cir-23-0577 · 2023 · External reference
IL-4 drives exhaustion of CD8+ CART cells
10.1038/s41467-024-51978-3 · 2024 · External reference
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
10.1182/blood-2018-01-828343 · 2018 · External reference
Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies
10.3389/fimmu.2024.1490911 · 2024 · External reference
EVEREST-1: safety and efficacy data of A2B530, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with solid tumors associated with carcinoembryonic antigen (CEA) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH)
10.1200/jco.2025.43.16_suppl.e16408 · 2025 · External reference
Assessment of functional status of human leukocyte antigen class I genes in cancer tissues in the context of personalized neoantigen peptide vaccine immunotherapy
10.1200/cci-24-00174 · 2025 · External reference
Pancreatic cancer
10.1016/s0140-6736(25)00261-2 · 2025 · External reference
Cancer statistics, 2025
2025 · External reference
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
10.1136/jitc-2020-001743 · 2021 · External reference
Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy
10.18632/oncotarget.27731 · 2020 · External reference
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
10.1016/s2352-3026(25)00117-6 · 2025 · External reference
Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome
10.1158/1078-0432.ccr-17-3649 · 2018 · External reference
PD-1 inhibition-trouble for subsequent TIL therapy in patients with melanoma?
10.1158/1078-0432.ccr-22-0832 · 2022 · External reference
Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma
10.1158/1078-0432.ccr-21-1171 · 2021 · External reference
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
10.1182/blood.2023023557 · 2024 · External reference
Preclinical analysis of ciltacabtagene autoleucel combination strategies with T cell bispecifics and daratumumab to support optimization of clinical benefit in myeloma patients
10.1182/blood-2024-211334 · 2024 · External reference
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
10.1182/blood.2024024526 · 2024 · External reference
